Bausch + Lomb Corp's stock increased by 3.06% in the last trading session, reflecting positive investor sentiment.
In the latest trading session, Bausch + Lomb Corp (BLCO.TO) closed at CA$21.24, showing a significant uptick. This rise follows strategic developments that have boosted investor confidence in the companyโs future prospects.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.16B
52W high
$25.70
52W low
$18.24
1W change
-5.71%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to fall 17.6% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$18.92
-17.6% Upside
Current Price
C$22.96
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
32.9%
Annualized
90-Day Vol
31.1%
Annualized
Trend (90d)
+2.8%
Annualized drift
90d Mean
C$23.19
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$23.04 | C$20.56 โ C$25.81 |
| 60 trading days | C$23.11 | C$19.68 โ C$27.14 |
| 90 trading days | C$23.19 | C$19.05 โ C$28.23 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the implications of Bausch + Lomb's recent strategic financing involvement with Emmecell, which may enhance its position in the ophthalmic treatment market.
Bausch + Lomb Corp Stock Climbs 3.06%
The stock's rise to CA$21.24 reflects growing optimism among investors, driven by strategic partnerships and advancements in technology.
Bull case
The successful closing of a strategic financing round involving Bausch + Lomb and Emmecell shows the company's commitment to innovation in ophthalmic therapies. This could lead to increased market share and revenue growth.
Bear case
Despite the positive movement, Bausch + Lomb faces ongoing challenges with profitability and a negative profit margin, which may raise concerns about its long-term financial health.
Strategic Financing with Emmecell
Bausch + Lomb's participation in Emmecell's recent financing round highlights its dedication to advancing innovative treatments for corneal diseases. This partnership may pave the way for new therapies that address significant unmet needs in ophthalmology.
Market Response and Future Outlook
The market's positive response to Bausch + Lomb's stock reflects investor confidence in its growth trajectory. As the company continues to invest in cutting-edge technologies, it could enhance its competitive edge in the healthcare sector.
Advertisement
